Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Climb Bio Q3 EPS $(0.19) Misses $(0.14) Estimate

Author: Benzinga Newsdesk | November 06, 2025 07:28am
Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.14) by 31.94 percent. This is a 46.15 percent decrease over losses of $(0.13) per share from the same period last year.

Posted In: CLYM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist